Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective

No single effective therapy for alcohol abuse has been found, despite it being a serious sociological and economic problem for hundreds of years. It seems difficult to find a single drug as a panacea for the alcohol problem due to the complexity of the pathophysiology of alcohol dependence. The purpose of this narrative review is to review existing and potentially future pharmaceuticals for the treatment of alcohol dependence in the most affordable way possible. Psychotherapy is the mainstay of treatment for alcoholism, while few drugs approved by legislators are available in the augmentation of this treatment, such as acamprosate, disulfiram, and naltrexone, approved by the FDA, and nalmefene by the EMA. There are recent reports in the literature on the possibility of using baclofen, topiramate, varenicline, and gabapentin in the treatment of alcohol dependence. Moreover, the results of recent clinical trials using psychoactive substances such as psilocybin and MDMA appear to be a breakthrough in the modern treatment of alcohol abuse. Despite this initial optimism, a lot of scientific effort is still needed before new pharmacological methods supporting the treatment of alcohol dependence syndrome will be widely available.

 

Comments：

It is true that the treatment of alcohol dependence is a complex issue and there is no single therapy that can be considered as a cure. Psychotherapy has proven to be an effective form of treatment, but it may not be enough for some patients, especially those with more severe forms of alcohol dependence. That is why the use of medications in combination with psychotherapy can be beneficial.

The FDA-approved drugs, acamprosate, disulfiram, and naltrexone, as well as the EMA-approved drug, nalmefene, have been shown to be effective in reducing alcohol consumption in some patients. However, their efficacy may vary from person to person and they may not work for everyone.

There are also newer medications, such as baclofen, topiramate, varenicline, and gabapentin, which have shown promising results in the treatment of alcohol dependence. However, more research is needed to confirm their effectiveness and safety.

The use of psychoactive substances, such as psilocybin and MDMA, in the treatment of alcohol dependence is a relatively new area of research and the initial results are promising. However, more controlled clinical trials are needed to determine the safety and efficacy of these substances in the treatment of alcohol dependence.

In conclusion, the treatment of alcohol dependence is a complex issue that requires a multi-disciplinary approach. The use of medications in combination with psychotherapy can be beneficial, but there is still a need for more research to find new and effective treatments for this condition.

Related Products

Cat.No.	Product Name	Information
S1680	Disulfiram	Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH) with IC50 of 0.15 μM and 1.45 μM for hALDH1 and hALDH2, respectively. Disulfiram is used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. Disulfiram induces apoptosis. Disulfiram is also an inhibitor of pore formation by gasdermin D (GSDMD).

Related Targets

Dehydrogenase Apoptosis related Pyroptosis COVID-19